Abstract 6911: Expanding reported molecular characteristics for the NCI Patient-Derived Models Repository

Cindy R. Timme,Yvonne A. Evrard,Biswajit Das,Ting-Chia Chang,Alice Chen,Li Chen,Michelle A. Crespo-Eugeni,Shahanawaz Jiwani,Chris A. Karlovich,Rini Pauly,Peter I-Fan Wu,Dianne L. Newton,P. Mickey Williams,Melinda G. Hollingshead,James H. Doroshow
DOI: https://doi.org/10.1158/1538-7445.am2024-6911
IF: 11.2
2024-03-31
Cancer Research
Abstract:The National Cancer Institute's Patient-Derived Models Repository (NCI PDMR; https://pdmr.cancer.gov) has developed a national repository of Patient-Derived Models (PDMs) comprised of patient-derived xenografts (PDXs), in vitro patient-derived tumor cell cultures (PDCs) and cancer associated fibroblasts (CAFs) as well as patient-derived organoids (PDOrg). These PDMs are clinically annotated with molecular information available in an easily accessible database for the extramural community. To ensure the data and models remains pertinent to current translational efforts, NCI actively reviews and adds new molecular features to the public database for researchers to use. While these data could be obtained through analysis of the available NextGen sequencing files in the PDMR database, many laboratories do not have the bioinformatics support to run these assessments for models that are of research interest. Therefore, new pipelines for an array of additional model and molecular characteristics present in PDX, PDOrg, and PDC models have been validated and are reported in the public database in a searchable format. Current model characteristics include addition of OncoTree Codes as a second histologic classifier, use of the PDXNet Consortium's inferred ancestry caller to better represent Native/Latin American populations, human leukocyte antigen (HLA) typing, molecular classification of tumors (e.g. CMS subtyping of colorectal adenocarcinoma, PAM50 signature based subtyping of breast carcinoma), microsatellite instability (MSI) assessment, and identification of clinically relevant fusions. SOPs for the pipelines used are available on the public website to allow for independent validation and use by other laboratories. Funded by NCI Contract No. HHSN261200800001E Citation Format: Cindy R. Timme, Yvonne A. Evrard, Biswajit Das, Ting-Chia Chang, Alice Chen, Li Chen, Michelle A. Crespo-Eugeni, Shahanawaz Jiwani, Chris A. Karlovich, Rini Pauly, Peter I-Fan Wu, Dianne L. Newton, P. Mickey Williams, Melinda G. Hollingshead, James H. Doroshow. Expanding reported molecular characteristics for the NCI Patient-Derived Models Repository [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 6911.
oncology
What problem does this paper attempt to address?